Logo image
Back
Barriers to Adherence with Corticosteroid Eye Drops in Patients with Uveitis
Journal article   Open access   Peer reviewed

Barriers to Adherence with Corticosteroid Eye Drops in Patients with Uveitis

Karen Sun, Rayna Marshall, Michael Frankland, Amal Taylor, Cynthia Montana, Eric Crowell, Karen R. Armbrust, Laura Kopplin and Meghan Berkenstock
Journal of current ophthalmology, v 37(2), pp 240-246
01 Apr 2025
DOI: https://doi.org/10.4103/joco.joco_239_24
PMID: 41488711
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.4103/joco.joco_239_24View
Published, Version of Record (VoR) Open

Abstract

Life Sciences & Biomedicine Science & Technology Ophthalmology
Purpose:To assess the patient barriers to adherence with corticosteroid eye drops in patients with ocular inflammatory disorders across the United States.Methods:This was a multicenter study of adult and pediatric patients with uveitis undergoing treatment with corticosteroid eye drops. Sites included the Johns Hopkins Wilmer Eye, the University of Texas at Austin, the University of Wisconsin-Madison, the University of Minnesota, the Minneapolis Veterans Administration Hospital, and the Washington University of St. Louis. Eligible patients completed a self-reporting survey to assess barriers to adherence with corticosteroid eye drops.Results:The survey was completed fully by 94 subjects and partially by 20 (115 in total), of whom were 66% White, 60% female, and 47% had a college or advanced degree. While some patients (5.5%, n = 6) self-reported never taking their corticosteroid eye drops as prescribed, most reported taking the drops as directed (54.1%, n = 59) or at least 90% of the time (29.4%, n = 32). Reasons for nonadherence were explored: 56% of patients used a corticosteroid eye drop more than once a day, and 13% found frequency a limitation to adherence. Many patients had polypharmacy, 43% took 4 or more medications, and 50% took 1 or more drops in addition to a corticosteroid eye drop. Patients also reported difficulty reading the writing on drop bottles (39%) and poor vision limiting application into the eye (17%). Almost a quarter (24%) of patients occasionally ran out of their drop before the next refill. Most patients did not report cost (98%) or insurance loss (97%) as a barrier to obtaining a refill.Conclusions:Barriers to corticosteroid eye drop treatments for ocular inflammatory disease include difficulty with medication frequency, polypharmacy, medication administration, missing refills, and running out of medication early. Addressing these barriers may improve adherence with corticosteroid eye drops to achieve treatment goals.

Metrics

1 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Ophthalmology
Logo image